Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics

Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise

India’s biotech economy set to reach a massive $300 bn by 2030: Dr. Jitendra Singh

Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored

Zydus receives final approval from USFDA for Dasatinib Tablets

Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase

Zydus Lifesciences launches ANVIMO

ANVIMO will be available in dosages of 240 mg and 480 mg

India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain

Teva and Sanofi present new outcome from Phase 2b study of duvakitug

Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025

India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant

We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner

GSK's Nucala application for COPD accepted for review in China

Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally

Senores Pharmaceuticals acquires ANDA for Roflumilast 250 mcg and 500 mcg tablets

Boehringer's zongertinib receives Priority Review from USFDA for the treatment of HER2 mutant advanced non-small cell lung cancer

Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved